Innovative Nanovesicle Formulation Enhances Cancer Drug Delivery and Efficacy
A newly developed nanovesicle formulation of paclitaxel improves targeted delivery to tumors, reduces side effects, and enhances the efficacy of combination cancer therapies, paving the way for advanced treatment options.
Researchers at the University of Arizona have developed a novel method to improve the delivery of chemotherapy drugs, specifically targeting pancreatic and breast cancer tumors. This new formulation employs tiny, fatty nanovesicles to carry the drug paclitaxel directly to tumor sites, reducing damage to healthy tissues and enhancing therapeutic effectiveness.
Traditionally, paclitaxel, also known by brand names like Taxol and Abraxane, is effective against various cancers such as breast, pancreatic, lung, and ovarian cancer. However, its use is limited by its toxicity and tendency to accumulate in non-target organs. The innovative approach modifies paclitaxel by chemically attaching it to sphingomyelin, a lipid found in cell membranes, which forms nanovesicles capable of better tumor penetration.
These nanovesicles improve drug circulation time, enabling higher concentrations of paclitaxel to reach and stay within tumor tissues while minimizing exposure to healthy organs. In preclinical tests involving mice with triple-negative breast cancer and advanced pancreatic cancer, the new drug, named Paclitaxome, outperformed existing formulations. The team further refined this technology, creating an improved version (CD47p/AZE-Paclitaxome), which significantly reduced tumor growth and extended the survival of animal models.
Beyond its standalone potency, Paclitaxome demonstrated superior delivery of drug combinations. For instance, when gemcitabine was incorporated into the nanovesicle core along with paclitaxel, the combination exceeded the effectiveness of conventional co-administration. Additionally, pairing the modified paclitaxel with carboplatin showed promise in preventing recurrence of triple-negative breast cancer and eliminating metastases.
The versatility of this nanovesicle platform suggests potential applications beyond these cancers, including delivering other chemotherapy drugs and immunotherapies. The researchers aim to advance this technology into first-in-human clinical trials, offering hope for more targeted, effective, and less toxic cancer treatments.
Source: https://medicalxpress.com/news/2025-08-repackaged-cancer-drug-boosts-delivery.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into Diabetic Neuropathy: The Role of Nageotte Nodules and Sensory Cell Degeneration
New research highlights the significance of Nageotte nodules—clusters of dead neurons—in the progression of diabetic neuropathy. These findings could lead to novel neuroprotective treatments targeting nerve degeneration in diabetes-related pain.
Medicaid and Cancer Screening: Trends, Barriers, and Strategies in New Jersey
New Jersey's Medicaid program is pivotal in increasing cancer screening rates, but barriers remain. Recent research highlights progress, challenges, and strategies to improve early detection through culturally competent outreach and policy support.
USPSTF Recommends Screening Women of Reproductive Age for Intimate Partner Violence
The USPSTF recommends routine screening of women of reproductive age for intimate partner violence to facilitate care and support, based on recent evidence reviews.
Breakthrough in Understanding Rare Multi-Organ Disease Unveils New Pathways for Treatment
Researchers have identified mutations in the SPNS1 gene as the cause of a rare multi-organ disease, paving the way for targeted therapeutic strategies and improved patient outcomes.